Sign In
Buy SITC
$4.88
-0.0500 (-1.01%)
At Close: Jun 03, 2026
WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo
SITE Centers Reports Third Quarter 2024 Results
08:00am, Wednesday, 30'th Oct 2024
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers primarily in suburban, high household income communities, announced today operating results for
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
07:00am, Wednesday, 30'th Oct 2024
- Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024 ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- I-Mab (NA
SAN JOSE, Calif. , Oct. 28, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
08:10am, Monday, 28'th Oct 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based
67 October Graham All-Star Value Dogs Show 55 Fit To Buy
02:49pm, Wednesday, 23'rd Oct 2024
The Value Score identifies large-cap stocks offering high-value relative to profits, cash flows, assets and sales, aiding in finding undervalued companies.
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
08:45am, Tuesday, 22'nd Oct 2024
FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology techn
SITE Centers' Third Quarter 2024 Earnings to be Released Wednesday, October 30, 2024
04:05pm, Monday, 21'st Oct 2024
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC) announced today that it intends to release its third quarter earnings prior to the market open on October 30, 2024. About SITE Centers
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
07:30am, Wednesday, 16'th Oct 2024
PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today
SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, toda
HAMILTON, Bermuda, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for soli
WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
09:10am, Friday, 04'th Oct 2024
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
09:07am, Friday, 04'th Oct 2024
Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
09:05am, Friday, 04'th Oct 2024
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer im
